These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 17020653

  • 21. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
    Taranta-Janusz K, Zoch-Zwierz W, Wasilewska A, Tenderenda E, Korzeniecka-Kozerska A.
    Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
    [Abstract] [Full Text] [Related]

  • 22. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes.
    Kadoglou NP, Vrabas IS, Sailer N, Kapelouzou A, Fotiadis G, Noussios G, Karayannacos PE, Angelopoulou N.
    Diabetes Metab; 2010 Apr; 36(2):144-51. PubMed ID: 20149706
    [Abstract] [Full Text] [Related]

  • 23. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF.
    Endothelium; 2006 Apr; 13(3):227-31. PubMed ID: 16840178
    [Abstract] [Full Text] [Related]

  • 24. [Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents].
    Głowińska-Olszewska B, Urban M, Florys B.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Apr; 12(3):179-83. PubMed ID: 17020652
    [Abstract] [Full Text] [Related]

  • 25. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
    Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, D'Angelo A.
    Endothelium; 2007 Apr; 14(4-5):175-83. PubMed ID: 17922333
    [Abstract] [Full Text] [Related]

  • 26. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
    Paśnik J, Cywińska-Bernas A, Moll J, Moll J, Sysa A, Zeman K.
    Przegl Lek; 2009 Apr; 66(7):359-64. PubMed ID: 20043576
    [Abstract] [Full Text] [Related]

  • 27. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [Abstract] [Full Text] [Related]

  • 28. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D, Stefanescu M, Blidaru A, Condrea I, Pistol G, Matache C.
    Roum Arch Microbiol Immunol; 2004 Feb; 63(3-4):141-58. PubMed ID: 17240786
    [Abstract] [Full Text] [Related]

  • 29. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE.
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [Abstract] [Full Text] [Related]

  • 30. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J, Patal S, Wexler D, Roth A, Sheps D, Keren G.
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [Abstract] [Full Text] [Related]

  • 31. Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure.
    Papadopoulos DP, Makris TK, Krespi PG, Poulakou M, Papazachou OG, Hatzizacharias AN, Perrea D, Votteas V.
    Eur Cytokine Netw; 2005 Sep; 16(3):211-4. PubMed ID: 16266862
    [Abstract] [Full Text] [Related]

  • 32. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.
    Cancer Lett; 2006 May 08; 236(1):125-32. PubMed ID: 15982804
    [Abstract] [Full Text] [Related]

  • 33. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
    Clin Neurol Neurosurg; 2006 Feb 08; 108(2):124-8. PubMed ID: 16412833
    [Abstract] [Full Text] [Related]

  • 34. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV, Savenkova OV, Kondakova IV, Perel'muter VM, Choĭnzonov EL, Shishkin DA.
    Vopr Onkol; 2007 Feb 08; 53(1):26-31. PubMed ID: 17649730
    [Abstract] [Full Text] [Related]

  • 35. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.
    Rheumatology (Oxford); 2006 Apr 08; 45(4):414-20. PubMed ID: 16287916
    [Abstract] [Full Text] [Related]

  • 36. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P.
    Nephrol Dial Transplant; 2007 Apr 08; 22(4):1115-22. PubMed ID: 17205957
    [Abstract] [Full Text] [Related]

  • 37. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T, Matsuda T, Suzuki Y, Ueda Y, Koide H.
    ASAIO J; 2003 Apr 08; 49(4):430-4. PubMed ID: 12918586
    [Abstract] [Full Text] [Related]

  • 38. Proteolytic and cytokine balance abnormalities in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass.
    Paśnik J, Moll J, Cywińska-Bernas A, Moll J, Sysa A, Zeman K.
    Kardiol Pol; 2007 Oct 08; 65(10):1208-14; discussion 1215. PubMed ID: 17979049
    [Abstract] [Full Text] [Related]

  • 39. Different circulating metalloproteinases profiles in women with migraine with and without aura.
    Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 Oct 08; 408(1-2):60-4. PubMed ID: 19627981
    [Abstract] [Full Text] [Related]

  • 40. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 May 08; 403(1-2):173-7. PubMed ID: 19254704
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.